Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Peter Lin MD, CCFP
Peter Lin MD, CCFP Associate Editor
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
See All Experts
Published in Primary Care and
2 other channels

News · June 15, 2022

ADA 2022: Once-Weekly Tirzepatide May Slow Kidney Disease Progression With Type 2 Diabetes

Tirzepatide is a once-weekly, injectable dual glucose-dependent insulinotropic polypeptide and GLP1 receptor agonist

PracticeUpdate Editorial Team

 

 Save  Recommend
 Share

Further Reading

Most Read This Week

Recently Updated